|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 209.03 USD | +4.96% |
|
+0.27% | +18.77% |
| 12:38am | Leqembi can now be administered at home from the start of treatment in the US | FW |
| 09:03pm | FDA Approves Eisai, Biogen's LEQEMBI Injection for Early Alzheimer's | MT |
| Market Cap | 30.86B 27.07B 25.07B 23.07B 43.63B 2,954B 44.48B 299B 117B 1,451B 116B 113B 5,009B | P/E 2026 * |
34.8x | P/E 2027 * | 17.5x |
|---|---|---|---|---|---|
| Enterprise Value | 36.37B 31.9B 29.54B 27.18B 51.42B 3,481B 52.42B 352B 138B 1,709B 137B 134B 5,904B | EV / Sales 2026 * |
3.61x | EV / Sales 2027 * | 3.29x |
| Free-Float |
85.96% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Biogen Inc.
| 1 day | +4.96% | ||
| 1 week | +0.27% | ||
| Current month | -3.25% | ||
| 1 month | +4.49% | ||
| 3 months | +18.52% | ||
| 6 months | +17.23% | ||
| Current year | +18.77% |
| 1 week | 194.37 |  | 210.87 |
| 1 month | 193.2 | | 219.72 |
| Current year | 160.36 | | 219.72 |
| 1 year | 121.05 | | 219.72 |
| 3 years | 110.04 | | 281.12 |
| 5 years | 110.04 | | 351.86 |
| 10 years | 110.04 | | 468.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 66 | 2022-11-13 | |
Robin Kramer
DFI | Director of Finance/CFO | 60 | 2025-02-28 |
Guy Hadari
CTO | Chief Tech/Sci/R&D Officer | - | 2020-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Eric Rowinsky
BRD | Director/Board Member | 69 | 2010-03-22 |
Stephen Sherwin
BRD | Director/Board Member | 77 | 2009-12-31 |
William Hawkins
BRD | Director/Board Member | 72 | 2019-06-18 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| Jun. 08 | Free | Director | 1,505 | 0.0010% | ||
| Jun. 08 | Free | Director | 1,505 | 0.0010% | ||
| Jun. 08 | Free | Director | 1,505 | 0.0010% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.96% | +0.27% | +55.75% | -24.80% | 30.86B | |
| -0.22% | +2.04% | +16.79% | -8.03% | 67.46B | |
| -0.72% | -7.84% | +35.55% | +194.88% | 51.13B | |
| +0.36% | +40.00% | +40.00% | +40.00% | 43.4B | |
| +1.34% | -0.81% | -49.11% | -52.89% | 40.32B | |
| -1.85% | -18.08% | +99.20% | -47.07% | 26.59B | |
| -2.12% | -1.20% | +66.54% | +84.42% | 22.82B | |
| +1.07% | +3.27% | +9.82% | +177.50% | 19.79B | |
| -0.54% | -4.50% | +55.11% | +125.27% | 16.47B | |
| -3.27% | +6.86% | +78.78% | +379.95% | 16.29B | |
| Average | +0.19% | -2.58% | +40.84% | +86.92% | 33.51B | |
| Weighted average by Cap. | +0.32% | -2.57% | +32.73% | +61.77% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10.06B 8.83B 8.18B 7.52B 14.23B 963B 14.51B 97.44B 38.22B 473B 37.79B 36.97B 1,634B | 10.4B 9.12B 8.45B 7.77B 14.7B 995B 14.99B 101B 39.48B 489B 39.04B 38.19B 1,688B |
| Net income | 1.39B 1.22B 1.13B 1.04B 1.97B 133B 2.01B 13.49B 5.29B 65.5B 5.23B 5.12B 226B | 1.97B 1.73B 1.6B 1.47B 2.78B 188B 2.84B 19.05B 7.47B 92.5B 7.39B 7.23B 319B |
| Net Debt | 5.51B 4.83B 4.48B 4.12B 7.79B 527B 7.94B 53.34B 20.92B 259B 20.69B 20.23B 894B | 3.38B 2.97B 2.75B 2.53B 4.79B 324B 4.88B 32.77B 12.85B 159B 12.71B 12.43B 549B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-13 | $209.03 | +4.96% | 2,259,821 |
| 26-07-10 | $199.15 | +0.12% | 1,133,120 |
| 26-07-09 | $198.91 | -0.72% | 1,657,327 |
| 26-07-08 | $200.36 | -2.60% | 1,947,888 |
| 26-07-07 | $205.70 | -1.32% | 1,156,880 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BIIB Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
